HLA-C and neoplasm: Tumor immunogenicity from frameshift mutations occur through the novel immunogenic FSPs that are presented by major histocompatibility complex (MHC) class-I molecules on tumor cells and by MHC class-I and II on antigen-presenting cells (APCs), being recognized as non-self.